The Experts below are selected from a list of 213 Experts worldwide ranked by ideXlab platform
Luiz C. Falchi - One of the best experts on this subject based on the ideXlab platform.
-
Pseudo-Meigs' syndrome associated to renal pelvis Tumor
International Braz J Urol, 2005Co-Authors: Chiara Scaglioni Tessmer, Franklin Correa Barcellos, Luiz C. FalchiAbstract:INTRODUCTION: Pseudo-Meigs' syndrome is associated with Tumors different from the benign Ovary Tumor, but it has never been described in association to transitional cell carcinoma. CASE REPORT: A female 73 year-old patient presenting pleural effusion nonmetastatic associated with renal pelvis transitional cell carcinomathat resolved and did not recur after radical nephroureterectomy. COMMENTS: Renal pelvis transitional cell carcinoma can result in the Pseudo-Meigs' syndrome. Although being a rare clinical entity, the identification of such syndrome can result in an accurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.
-
pseudo meigs syndrome associated to renal pelvis Tumor
International Braz J Urol, 2005Co-Authors: Chiara Scaglioni Tessmer, Franklin Correa Barcellos, Luiz C. FalchiAbstract:ABSTRACTIntroduction: Pseudo-Meigs’ syndrome is associated with Tumors different from the benignOvary Tumor, but it has never been described in association to transitional cell carcinoma.Case Report: A female 73 year-old patient presenting pleural effusion nonmetastatic associ-ated with renal pelvis transitional cell carcinomathat resolved and did not recur after radicalnephroureterectomy.Comments: Renal pelvis transitional cell carcinoma can result in the Pseudo-Meigs’ syn-drome. Although being a rare clinical entity, the identification of such syndrome can result in anaccurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.Key words : kidney; carcinoma, transitional cell; Meigs’ syndrome; pleural effusionInt Braz J Urol. 2005; 31: 256-8 INTRODUCTION Meigs & Cass (1) described the Meigs’ syn-drome from case reports of patients with right pleu-ral effusion and ascites associated with benign OvaryTumor, which were resolved after the removal of theovarian lesion. The name pseudo-Meigs’ syndromeis used to describe the same clinical situation, butonly when it is caused by Tumors different from be-nign Ovary Tumor (1).
Chiara Scaglioni Tessmer - One of the best experts on this subject based on the ideXlab platform.
-
Pseudo-Meigs' syndrome associated to renal pelvis Tumor
International Braz J Urol, 2005Co-Authors: Chiara Scaglioni Tessmer, Franklin Correa Barcellos, Luiz C. FalchiAbstract:INTRODUCTION: Pseudo-Meigs' syndrome is associated with Tumors different from the benign Ovary Tumor, but it has never been described in association to transitional cell carcinoma. CASE REPORT: A female 73 year-old patient presenting pleural effusion nonmetastatic associated with renal pelvis transitional cell carcinomathat resolved and did not recur after radical nephroureterectomy. COMMENTS: Renal pelvis transitional cell carcinoma can result in the Pseudo-Meigs' syndrome. Although being a rare clinical entity, the identification of such syndrome can result in an accurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.
-
pseudo meigs syndrome associated to renal pelvis Tumor
International Braz J Urol, 2005Co-Authors: Chiara Scaglioni Tessmer, Franklin Correa Barcellos, Luiz C. FalchiAbstract:ABSTRACTIntroduction: Pseudo-Meigs’ syndrome is associated with Tumors different from the benignOvary Tumor, but it has never been described in association to transitional cell carcinoma.Case Report: A female 73 year-old patient presenting pleural effusion nonmetastatic associ-ated with renal pelvis transitional cell carcinomathat resolved and did not recur after radicalnephroureterectomy.Comments: Renal pelvis transitional cell carcinoma can result in the Pseudo-Meigs’ syn-drome. Although being a rare clinical entity, the identification of such syndrome can result in anaccurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.Key words : kidney; carcinoma, transitional cell; Meigs’ syndrome; pleural effusionInt Braz J Urol. 2005; 31: 256-8 INTRODUCTION Meigs & Cass (1) described the Meigs’ syn-drome from case reports of patients with right pleu-ral effusion and ascites associated with benign OvaryTumor, which were resolved after the removal of theovarian lesion. The name pseudo-Meigs’ syndromeis used to describe the same clinical situation, butonly when it is caused by Tumors different from be-nign Ovary Tumor (1).
L. L. Vorontsova - One of the best experts on this subject based on the ideXlab platform.
-
Pathogenetic rationale for the use of immunomodulating and systemic enzyme therapy in treatment of nulliparous women with endometrioid Ovary Tumors = Патогенетическое обоснование применения иммуномодулирующей и системной энзимотерапии в комплексном л
Journal of Education Health and Sport, 2015Co-Authors: O. S. Shapoval, L. L. VorontsovaAbstract:The modern approach to the treatment options and assessment of its effectiveness in nulliparous women with endometrial cysts is build on optimal pathogenetically substantiated therapy based on features of the disease not only on the system, organ and tissue levels, and taking to consideration the cellular and molecular features of the functioning of the body. Therefore, the aim of our work was to determine the effectiveness of various treatment regimens for nulliparous women with Ovary Tumor-like formations based on features of the immune status. In the study of immune status in nulliparous women with endometrioid Tumorlike formations of ovaries (n = 30) was the inconsistency of the phagocytic system, the imbalance of Tand B-cell immunity, dysimmunoglobulinemy. Based on the identification of changes, the patients were assigned with pathogenetically
-
Pathogenetic rationale for the use of immunomodulating and systemic enzyme therapy in treatment of nulliparous women with endometrioid Ovary Tumors
Journal of Education Health and Sport, 2015Co-Authors: O. S. Shapoval, L. L. VorontsovaAbstract:Shapoval O. S., Vorontsova L. L. Pathogenetic rationale for the use of immunomodulating and systemic enzyme therapy in treatment of nulliparous women with endometrioid Ovary Tumors = П атогенетическое обоснование применения иммуномодулирующей и системной энзимотерапии в комплексном лечении нерожавших женщин с опухолеподобными образованиями яичников . Journal of Education, Health and Sport. 2015;5(1):75-86. ISSN 2391-8306 . DOI: 10.5281/zenodo.13992 http://ojs.ukw.edu.pl/index.php/johs/article/view/2015%3B5%281%29%3A75-86 https://pbn.nauka.gov.pl/works/527872 http://dx.doi.org/10.5281/zenodo.13992 F ormerly Journal of Health Sciences. ISSN 1429-9623 / 2300-665X. Archives 2011 – 2014 http://journal.rsw.edu.pl/index.php/JHS/issue/archive Deklaracja. Specyfika i zawartośc merytoryczna czasopisma nie ulega zmianie. Zgodnie z informacją MNiSW z dnia 2 czerwca 2014 r., ze w roku 2014 nie bedzie przeprowadzana ocena czasopism naukowych; czasopismo o zmienionym tytule otrzymuje tyle samo punktow co na wykazie czasopism naukowych z dnia 31 grudnia 2014 r. The journal has had 5 points in Ministry of Science and Higher Education of Poland parametric evaluation. Part B item 1089. (31.12.2014). © The Author (s) 2015; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland and Radom University in Radom, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 15.06.2014. Revised 05.10.2014. Accepted: 25.12.2014. UDK 618.11 – 006.2:615.37 – 092] – 08 – 055.25 Pathogenetic rationale for the use of immunomodulating and systemic enzyme therapy in treatment of nulliparous women with endometrioid Ovary Tumors П атогенетическое обоснование применения иммуномодулирующей и системной энзимотерапии в комплексном лечении нерожавших женщин с опухолеподобными образованиями яичников O. S. Shapoval, L. L. Vorontsova О. С. Шаповал, Л. Л. Воронцова State establishment «Zapor о zhy e Medical Academy of Post-Graduate Education Ministry of Health of Ukraine», Zaporоzhye, Ukraine ГЗ «Запорожская медицинская академия последипломного образования МЗ Украины», Запорожье Department of Obstetrics and Gynaecology Department of Clinical Laboratory Diagnostics e-mail: shapoval_olga@ukr.net Abstract The modern approach to the treatment options and assessment of its effectiveness in nulliparous women with endometrial cysts is build on optimal pathogenetically substantiated therapy based on features of the disease not only on the system, organ and tissue levels, and taking to consideration the cellular and molecular features of the functioning of the body. Therefore, the aim of our work was to determine the effectiveness of various treatment regimens for nulliparous women with Ovary Tumor-like formations based on features of the immune status. In the study of immune status in nulliparous women with endometrioid Tumor-like formations of ovaries (n = 30) was the inconsistency of the phagocytic system, the imbalance of T- and B-cell immunity, dysimmunoglobulinemy. Based on the identification of changes, the patients were assigned with pathogenetically substantiated combination therapy that included, in addition to conventional treatment regimens, the appointment of immunomodulators and systemic enzyme therapy. Treatment results show the full normalization of phagocytic, T- and B-cells and partially humoral systems. Key-words: immunomodulating therapy, nulliparous women, Tumor-like endometrioid ovarian formation. Резюме Современный подход выбора варианта лечения и оценки его эффективности у нерожавших женщин с эндометриоидными кистами состоит в формировании оптимальной патогенетически обоснованной терапии с учетом особенностей заболевания не только на системном, органном и тканевом уровнях, а и с учетом клеточно-молекулярных особенностей функционирования организма. В связи с этим целью нашей работы являлось выявление эффективности применения различных схем лечения нерожавших женщин с опухолеподобными образованиями яичников с учетом особенностей иммунного статуса. При исследовании иммунного статуса у нерожавших женщин с опухолеподобными эндометриоидными образованиями яичников (n=30) была выявлена несостоятельность фагоцитарной системы, дисбаланс Т- и В-клеточного иммунитета, дизиммуноглобулинемия. основываясь на выявленных изменениях, пациенткам была назначена патогенетически обоснованная комбинированная терапия, включающая, помимо традиционной схемы лечения, назначение иммуномодуляторов и системной энзимотерапии. Результаты лечения свидетельствуют о полной нормализации показателей фагоцитарной, Т- и В-клеточной и, частично, гуморальной систем. Ключевые слова: иммуномодулирующая терапия, нерожавшие женщины, опухолеподобные эндометриоидные образования яичников.
Franklin Correa Barcellos - One of the best experts on this subject based on the ideXlab platform.
-
Pseudo-Meigs' syndrome associated to renal pelvis Tumor
International Braz J Urol, 2005Co-Authors: Chiara Scaglioni Tessmer, Franklin Correa Barcellos, Luiz C. FalchiAbstract:INTRODUCTION: Pseudo-Meigs' syndrome is associated with Tumors different from the benign Ovary Tumor, but it has never been described in association to transitional cell carcinoma. CASE REPORT: A female 73 year-old patient presenting pleural effusion nonmetastatic associated with renal pelvis transitional cell carcinomathat resolved and did not recur after radical nephroureterectomy. COMMENTS: Renal pelvis transitional cell carcinoma can result in the Pseudo-Meigs' syndrome. Although being a rare clinical entity, the identification of such syndrome can result in an accurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.
-
pseudo meigs syndrome associated to renal pelvis Tumor
International Braz J Urol, 2005Co-Authors: Chiara Scaglioni Tessmer, Franklin Correa Barcellos, Luiz C. FalchiAbstract:ABSTRACTIntroduction: Pseudo-Meigs’ syndrome is associated with Tumors different from the benignOvary Tumor, but it has never been described in association to transitional cell carcinoma.Case Report: A female 73 year-old patient presenting pleural effusion nonmetastatic associ-ated with renal pelvis transitional cell carcinomathat resolved and did not recur after radicalnephroureterectomy.Comments: Renal pelvis transitional cell carcinoma can result in the Pseudo-Meigs’ syn-drome. Although being a rare clinical entity, the identification of such syndrome can result in anaccurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.Key words : kidney; carcinoma, transitional cell; Meigs’ syndrome; pleural effusionInt Braz J Urol. 2005; 31: 256-8 INTRODUCTION Meigs & Cass (1) described the Meigs’ syn-drome from case reports of patients with right pleu-ral effusion and ascites associated with benign OvaryTumor, which were resolved after the removal of theovarian lesion. The name pseudo-Meigs’ syndromeis used to describe the same clinical situation, butonly when it is caused by Tumors different from be-nign Ovary Tumor (1).
Jeltsje S. Cnossen - One of the best experts on this subject based on the ideXlab platform.
-
The Accuracy of Risk Scores in Predicting Ovarian Malignancy
Obstetrics & Gynecology, 2020Co-Authors: Peggy M.a.j. Geomini, Roy F.p.m. Kruitwagen, Gérard L. Bremer, Jeltsje S. CnossenAbstract:OBJECTIVE: To perform a systematic review of the literature on the accuracy of prediction models in the preoperative assessment of adnexal masses. DATA SOURCES: Studies were identified through the MEDLINE and EMBASE databases from inception to March 2008. The MEDLINE search was performed using the keywords [“ovarian neoplasms”[MeSH] NOT “therapeutics”[MeSH] AND “model”] and [“ovarian neoplasms”[MeSH] NOT “therapeutics”[MeSH] AND “prediction”]. The Embase search was performed using the keywords [Ovary Tumor AND prediction], [Ovary Tumor AND Mathematical model], and [Ovary Tumor AND statistical model]. METHODS OF STUDY SELECTION: The search detected 1,161 publications; from the cross-references, another 116 studies were identified. Language restrictions were not applied. Eligible studies contained data on the accuracy of models predicting the risk of malignancy in ovarian masses. Models were required to combine at least two parameters. TABULATION, INTEGRATION, AND RESULTS: Two independent reviewers selected studies and extracted study characteristics, study quality, and test accuracy. There were 109 accuracy studies that met the selection criteria. Accuracy data were used to form two-by-two contingency tables of the results of the risk score compared with definitive histology. We used bivariate meta-analysis to estimate pooled sensitivities and specificities and to fit summary receiver operating characteristic curves. Studies included in our analysis reported on 83 different prediction models. The model developed by Sassone was the most evaluated prediction model. All models has acceptable sensitivity and specificity. However, the Risk of Malignancy Index I and the Risk of Malignancy Index II, which use the product of the serum CA 125 level, an ultrasound scan result, and the menopausal state, were the best predictors. When 200 was used as the cutoff level, the pooled estimate for sensitivity was 78% for a specificity of 87%. CONCLUSION: Based on our review, the Risk of Malignancy Index should be the prediction model of choice in the preoperative assessment of the adnexal mass.Peggy Geomini, Roy Kruitwagen, Gérard L. Bremer, Jeltsje Cnossen and Ben W. J. Mo
-
The Accuracy of Risk Scores in Predicting Ovarian Malignancy: A Systematic Review
Obstetrics & Gynecology, 2009Co-Authors: Peggy M.a.j. Geomini, Roy F.p.m. Kruitwagen, Gérard L. Bremer, Jeltsje S. CnossenAbstract:OBJECTIVE: To perform a systematic review of the literature on the accuracy of prediction models in the preoperative assessment of adnexal masses. DATA SOURCES: Studies were identified through the MEDLINE and EMBASE databases from inception to March 2008. The MEDLINE search was performed using the keywords ["ovarian neoplasms"[MeSH] NOT "therapeutics"[MeSH] AND "model"] and ["ovarian neoplasms"[MeSH] NOT "therapeutics"[MeSH] AND "prediction"]. The Embase search was performed using the keywords [Ovary Tumor AND prediction], [Ovary Tumor AND Mathematical model], and [Ovary Tumor AND statistical model]. METHODS OF STUDY SELECTION: The search detected 1,161 publications; from the cross-references, another 116 studies were identified. Language restrictions were not applied. Eligible studies contained data on the accuracy of models predicting the risk of malignancy in ovarian masses. Models were required to combine at least two parameters. TABULATION, INTEGRATION, AND RESULTS: Two independent reviewers selected studies and extracted study characteristics, study quality, and test accuracy. There were 109 accuracy studies that met the selection criteria. Accuracy data were used to form two-by-two contingency tables of the results of the risk score compared with definitive histology. We used bivariate meta-analysis to estimate pooled sensitivities and specificities and to fit summary receiver operating characteristic curves.Studies included in our analysis reported on 83 different prediction models. The model developed by Sassone was the most evaluated prediction model. All models has acceptable sensitivity and specificity. However, the Risk of Malignancy Index I and the Risk of Malignancy Index II, which use the product of the serum CA 125 level, an ultrasound scan result, and the menopausal state, were the best predictors. When 200 was used as the cutoff level, the pooled estimate for sensitivity was 78% for a specificity of 87%. CONCLUSION: Based on our review, the Risk of Malignancy Index should be the prediction model of choice in the preoperative assessment of the adnexal mass.
